Nasopharyngeal angiofibroma with intracellular accumulation of SPARC - a hypothesis (SPARC in nasopharyngeal angiofibroma)

Medical Hypotheses

Volumn 70, Issue 3, 2008, Pages 600-604

  Krstulja, Mira ^a   Car, Alenka ^a   Bonifačić, David ^a   Braut, Tamara ^b   Kujundžić, Milodar ^b  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; OSTEONECTIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COMPLEX FORMATION; HEMANGIOFIBROMA; NASOPHARYNX FIBROMA; PRIORITY JOURNAL; STROMA CELL;

ANGIOFIBROMA; ENDOTHELIUM, VASCULAR; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEONECTIN; STROMAL CELLS;

EID: 38849205493     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.011     Document Type: Article

References (57)

1. Liang J., Yi Z., and Lianq P. The nature of juvenile nasopharyngeal angiofibroma. Otolaryng Head Neck Surg 123 4 (2000) 475-481
2. Beham A., Beham-Schmid C., Regauer S., Aubock L., and Stammberger H. Nasopharyngeal angiofibroma: true neoplasm or vascular malformation?. Adv Anat Pathol 7 1 (2000) 36-46
3. Schick B., and Urbschat S. New aspects of pathogenesis of juvenile angiofibroma. Hospital medicine 65 5 (2004) 269-273
4. Schiff M., Gonzalez A., Ong M., and Baird A. Juvenil nasopharyngeal angiofibroma contains an angiogenic growth factor: basic FGF. Laryngoscope 102 (1992) 940-945
5. Nagai M.A., Butugan O., Logullo A., and Brentani M.M. Expression of growth factors, proto-oncogenes, and p53 in nasopharyngeal angiofibromas. Laryngoscope 106 2 Pt 1 (1996) 190-195
6. Zhang P.J., Weber R., Liang H.H., Pasha T.L., and LiVolsi V.A. Growth factors and receptors in juvenile nasopharyngeal angiofibroma and nasal polyps: an immunohistochemical study. Arch Pathol Lab Med 127 11 (2003) 1480-1484
7. Erovic B.M., Neuchrist C., Kandutsch S., Woegerbauer M., and Pammer J. CD9 expression on lymphatic vessels in head and neck mucosa. Mod Pathol 16 10 (2003) 1028-1034
8. Brieger J., Wierzbicka M., Sokolov M., Roth Y., Szyfter W., and Mann W.J. Vessel density, proliferation, and immunolocalization of vascular endothelial growth factor in juvenile nasopharyngeal angiofibromas. Arch Otolaryng Head Neck Surg 130 (2004) 727-731
9. Nozaki M., Sakurai E., Raisler B.J., Baffi J.Z., Witta J., Ogura Y., et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 116 2 (2006) 422-429
10. Stifter S. The role of nuclear factor kappaB on angiogenesis regulation through monocyte chemotactic protein-1 in myeloma. Med Hypotheses 66 2 (2006) 384-386
11. Saylam G., Yücel O., Sungur A., and Önerci M. Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Ped Otorhinolaryng 70 2 (2006) 227-234
12. Schuon R., Brieger J., Heinrich U.R., Roth Y., Szyfter W., and Wolf J Mann W.J. Immunohistochemical analysis of growth mechanisms in juvenile nasopharyngeal angiofibroma. Eur Arch Otorhinolaryng 264 4 (2007) 389-394
13. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 38 (1999) 5356-5362
14. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 2 (1999) 159-165
15. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., et al. Combined inhibition of VEGF and PDGF signalling enforces tumor vessel regression by interfering with pericyte - mediated endothelial-cell survival mechanisms. FASEB J 18 (2004) 338-340
16. DeRuiter M.C., Poelmann R.E., VanMunsteren J.C., Mironov V., Markwald R.R., and Gittenberger-de Groot A.C. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 80 (1997) 444-451
17. Augustin H.G. Tubes, branches, and pillars: the many ways of forming a new vasculature. Circ Res 89 (2001) 645-647
18. +-Enriched Cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108 17 (2003) 2070-2073
19. Beham A., Kainz J., Stammberger H., Aubock L., and Beham-Schmid C. Immunohistochemical and electron microscopical characterization of stromal cells in nasopharyngeal angiofibromas. Eur Arch Otorhinolaryng 254 4 (1997) 196-199
20. Yan Q., and Sage E.H. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 47 (1999) 1495-1506
21. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J Clin Invest 107 7 (2001) 785-790
22. Framson P.E., and Sage E.H. SPARC and tumor growth: Where the seed meets the soil?. J Cell Biochem 92 4 (2004) 679-690
23. Saaristo A., Taina A P., Johanna A., Lotta J., Maija H., Antti M., et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol 157 (2000) 7-14
24. Abraham S.C., Montgomery E.A., Giardiello F.M., and Tsung-Teh Wu T.T. Frequent β-Catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol 158 (2001) 1073-1078
25. Stiller D., Katenkamp D., and Küttner K. Cellular differentiations and structural characteristics in nasopharyngeal angiofibromas. Virchows Arch 371 (1973) 273-282
26. Beham A., Fletcher C.D.M., Kainz J., Schmid C., and Humer U. Nasopharyngeal angiofibroma: an immunohistochemical study of 32 cases. Virchows Arch 423 4 (1993) 281-285
27. Schick B., Veldung B., Wemmert S., Jung V., Montenarh M., Meese E., et al. p53 and Her-2/neu in juvenile angiofibromas. Oncol Rep 13 3 (2005) 453-457
28. Motamed K., and Sage E.H. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem 70 4 (1998) 543-552
29. Chlenski S.L., Crawford S.E., Volpert O.V., DeVries G.H., Evangelista A., Yang Q., et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62 (2002) 7357-7363
30. Schor A.M., Canfield A.E., Sutton A.B., Arciniegas E., and Allen T.D. Pericyte differentiation. Clin Orthop Relat Res 313 (1995) 81-91
31. Wrana J.L., Overall C.M., and Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor β. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 197 (1991) 519-528
32. Tremble P.M., Lane II T.E., Sage E.H., and Zena Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 121 6 (1993) 1433-1444
33. Chlenski A, Guerrero J, Yang Q, Tian Y, Peddinti R, Salwen HR, et al. SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene advance online publication 29 January 2007.
34. Gooden M.D., Vernon R.B., Bassuk J.A., and Sage E.H. Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix. J Cell Biochem 74 (1999) 152-167
35. Bradshaw A.D., Francki A., Motamed K., Howe C., and Sage E.H. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 10 5 (1999) 1569-1579
36. Shi Q., Bao S., Maxwell J., Reese E., Bigner D.D., Wang X.F., et al. Secreted protein acidic, rich in cysteine (SPARC) mediates cellular survival of glioma through Akt activity. J Biol Chem 279 (2004) 52200-52209
37. Sarmishtha D., Juhua C., Natalya N.V., Warren H., Jennifer B., Sage E.H., et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 278 40 (2003) 39044-39050
38. Kunigal S., Gondi C.S., Gujrati M., Lakka S.S., Dinh D.H., Olivero W.C., et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 29 (2006) 1349-1357
39. 1, Molecular Cancer Research 2 (2004) 215-224.
40. Hecht J.T., and Helene Sage E. Retention of the matricellular protein SPARC in the endoplasmic reticulum of chondrocytes from patients with pseudoachondroplasia, concentrated intracellular depots of SPARC were identified in nodules cultured from three PSACH patients with mutations in COMP. J Histochem Cytochem 54 3 (2006) 269-274
41. Kato Y., Lewalle J.-M., Baba Y., Tsukuda M., Sakai N., Baba M., et al. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 287 2 (2001) 422-426
42. Sundberg C., Kowanetz M., Brown L.F., Detmar M., and Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82 (2002) 387-401
43. Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P., et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278 39 (2003) 37849-37857
44. Delany A.M., and Canalis E. Basic fibroblast growth factor destabilizes osteonectin mRNA in osteoblasts. Am J Physiol Cell Physiol 274 (1998) C734-C740
45. Funk S.E., and Sage E.H. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 154 (1993) 53-63
46. Sivridis E., Giatromanolaki A., and Koukourakis M.I. Stromatogenesis and tumor progression. I J Surg Pathol 12 1 (2004) 1-9
47. Chlenski A., Liu S., Guerrero L.J., Yang Q., Tian Y., Helen R Salwen H.R., et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 118 2 (2005) 310-316
48. Papetti M., Shujath J., Riley K.N., and Herman I.M. FGF-2 antagonizes the TGF-ß1-mediated induction of pericyte α - smooth muscle actin expression: a role for Myf-5 and smad-mediated signaling pathways. Inv Ophthalmol Visual Sci 44 (2003) 4994-5005
49. Dillard D.G., Cohen C., Muller S., Del Gaudio J., Reichman O., B P., et al. Immunolocalization of activated transforming growth factor β1 in juvenile nasopharyngeal angiofibroma. Arch Otolaryng Head Neck Surg 126 (2000) 723-725
50. Shiba H., Uchida Y., Kamihagi K., Sakata M., Fujita T., Nakamura S., et al. Transforming growth factor-beta1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin-D-activated pulp cells. J Dent Res 80 7 (2001) 1653-1659
51. Reines E.W., Lanes T.F., Iruela-Arispe M.L., Ross R., and Sage E.H. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Nat Acad Sci USA 89 (1992) 281-285
52. Valanzano R., Curia M.C., Aceto G., Veschi S., De Lellis L., Catalano T., et al. Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour Gut 54 (2005) 1046-1047
53. Kupprion C., Motamed K., and Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273 (1998) 29635-29640
54. Rippel C., Plinkert P.K., and Schick B. Expression von Proteinen der Cadherin- und Catenin-Proteinfamilie bei juvenilen angiofibromen. Expression of members of the Cadherin-/Catenin-protein family in juvenile angiofibromas. Laryngorhinootologie 82 (2003) 353-357
55. Robert G., Gaggioli C., Bailet O., Chavey C., Abbe P., Aberdam E., et al. SPARC represses E-Cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66 (2006) 7516-7523
56. Armulik A., Abramsson A., and Betsholtz C. Endothelial/pericyte interactions. Circ Res 97 (2005) 512-516
57. Sennes L.U., Butugan O., Sanchez T.G., Bernardi Fdel C., and Saldiva P.H. Tissue maturation during the growth of juvenile nasopharyngeal angiofibroma. Ann Otol Rhinol Laryngol 113 1 (2004) 34-38